GEO Publications
Handout
NAR 2024 (latest)
NAR 2002 (original)
All publications
FAQ
MIAME
Email GEO
NCBI
>
GEO
>
Accession Display
Not logged in |
Login
GEO help:
Mouse over screen elements for information.
Scope:
Self
Platform
Samples
Series
Family
Format:
HTML
SOFT
MINiML
Amount:
Brief
Quick
GEO accession:
Sample GSM39499
Query DataSets for GSM39499
Status
Public on Apr 01, 2005
Title
pp83-2
Sample type
RNA
Source name
Staged C. elegans embryos
Organism
Caenorhabditis elegans
Extracted molecule
total RNA
Description
Mutant genotype pie-1(zu154); pal-1(RNAi) 83 minutes after the 4-cell embryonic stage at 22 degrees C
Sample_genotype: pp
Sample_time: 83
Submission date
Jan 24, 2005
Last update date
May 27, 2005
Contact name
Andrew Hill
E-mail(s)
andrew.hill@pfizer.com
Phone
617-674-6341
Organization name
Pfizer
Department
Research Business Technology
Street address
300 Technology Square
City
Cambridge
State/province
MA
ZIP/Postal code
02139
Country
USA
Platform ID
GPL200
Series (1)
GSE2180
C. elegans embryonic timecourse in wt and mutant embryos
Data table header descriptions
ID_REF
Affymetrix Qualifier
VALUE
RMA calulated using Bioconductor Affy package (http://www.bioconductor.org)
Data table
ID_REF
VALUE
171720_x_at
4.04194262740477
171721_x_at
6.12458585336266
171722_x_at
6.45204761357852
171723_x_at
3.50729431413219
171724_x_at
3.37880877858141
171725_x_at
4.33802192762958
171726_x_at
4.37351362452746
171727_x_at
2.65210427294644
171728_x_at
3.04878176675571
171729_x_at
7.21225627336685
171730_x_at
2.91806749846286
171731_x_at
8.05455846214812
171732_x_at
6.27928125626948
171733_x_at
3.61025001189253
171734_x_at
9.80489376061418
171735_x_at
3.24876259712701
171736_x_at
8.64857858323737
171737_x_at
6.57536942807588
171738_x_at
5.83519065905063
171739_x_at
3.35168616822429
Total number of rows:
22625
Table truncated, full table size
608 Kbytes
.
Supplementary file
Size
Download
File type/resource
GSM39499.CEL.gz
2.7 Mb
(ftp)
(http)
CEL
GSM39499.EXP.gz
332 b
(ftp)
(http)
EXP
|
NLM
|
NIH
|
GEO Help
|
Disclaimer
|
Accessibility
|
